When I finally agreed to attend this meeting I still was not sure that it was going to be the best investment of time and money – I am thrilled to say it was well worth both! In the past most meetings were a series of supplier commercials with some data sprinkled in. This meeting was just the opposite. AND, just as I was losing hope that the life sciences industry could truly put the patient at the center of its business decision-making my faith was renewed.
I will share some highlights here but kudos go to Q1 Productions for assembling a great group of attendees and putting together a solid agenda. I would like to see more opportunity for discussion and Q&A at this and other meetings but the Q1 staff were great hosts and we attendees made sure we spoke to who we needed.
You can see the entire agenda here – http://www.q1productions.com/rxpatientadherence/dayone.php#.UOw136Wl5Rs
Here are the highlights:
Almost every single speaker spoke about and shared real world examples of being patient/user centered while meeting or exceeding business objectives. It’s that “meeting or exceeding business objectives” part that, frankly, will enable this industry to work from this perspective.
KEY STAKEHOLDERS ROUNDTABLE DISCUSSION: ENHANCING PATIENT EDUCATION, ENGAGEMENT AND ADHERENCE – PANEL DISCUSSION
Peter Pitts, President
CENTER FOR MEDICINE IN THE PUBLIC INTEREST
ADVISOR TO OBAMA ADMINISTRATION FDA TRANSITION TEAM
CURASCRIPT, INC, EXPRESS SCRIPTS
Predictive behavior and consumerology philosophy combined with Medco science focus.
John P Burke III, Policy Advisor
Previously with MEDCO RESEARCH INSTITUTE
STRATEGIES AND INITIATIVES FOR OPTIMALLY EDUCATING PATIENTS ENROLLED IN CLINICAL DRUG TRIALS
Dorothy L. Smith, PharmD, CEO & President
CONSUMER HEALTH INFORMATION CORPORATION
Dr Smith raised the issue of non-adherence as it relates to drug safety, that patient adherence is the hidden problem in many clinical trials. The general assumption is that patients are 95% compliant in clinical trials. Dr Smith’s research belies this assumption. Her research shows that patients are much less adherent then believed, therefore decisions about dosage are over estimated resulting in the possibility of over-dosing. A recent example is the FDA guidance regarding reducing the dose of zolpidem for women http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334798.htm. For more information on the study “Patients in Clinical Trials May Be Putting the Public at Risk” please see this link http://www.consumer-health.com/press/2008/PatientsinClinicalTrialsMayBePuttingthePublicatRisk.php
EXPRESS SCRIPTS, INC.
We are asking people to change something they don’t even know is a problem
“a letter that combined authority (signed by doc), combined with loss aversion, (patients recognize what they will lose if they don’t adhere) is the most effective effort.
- Messages on pill cap, call your doc, no refills, new Rx required” on a cap for last bottle, increased refill in time rate, closed 230,000 gaps in care over six months
- Behavioral science and actionable data, 2,3, 6.3% improvement with dose alert
BUILDING PHARMACY & PHYSICIAN COLLABORATIONS TO ENSURE COMPLIANCE Gina Guinasso, JD, Director, Managed Markets
Kevin Cast, VP Strategy & Contracting
CURASCRIPT, INC, EXPRESS SCRIPTSDaniel Miller, PharmD, RPh, Health-Systems Pharmacy Manager
WALGREENS SPECIALTY PHARMACY
- Manufacturers are going to specialty pharmacy for adherence programs
- Medication Possession Ratio (MPR) is the measure
- Specialty pharmacy builds hubs to manage patients, track adherence , can do more meeting stuff within a hub